Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy

• Status: Completed
• Trial end date: 2013-01-01

Summary

Our first hypothesis is that dose adjustment of aspirin and clopidogrel based on biological monitoring reduces the rate of severe cardiovascular complications compared to a conventional strategy in patients scheduled for drug eluting stent implantation and followed up for one year. Our second hypothesis is that interruption of clopidogrel / Prasugrel after one year of a combined therapy of clopidogrel/Prasugrel and aspirin is associated with a higher rate of severe cardiovascular complications as compared with patients in whom aspirin and clopidogrel / Prasugrel is maintained during the subsequent 6 months of follow-up.

• Phase: Phase 4

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Allies in Cardiovascular Trials Initiatives and Organized; Boston Scientific Corporation; Bristol-Myers Squibb; Cordis Corporation; Diagnostica Stago; Fondation de France; Institut National de la Santé Et de la Recherche Médicale, France; Medtronic; Sanofi
• Treatments: Aspirin; Clopidogrel; Prasugrel Hydrochloride; Ticlopidine